vTv Therapeutics Q2 net loss widens on higher trial costs

vTv Therapeutics

06/08/2026 13:18

Overview
US biopharmaceutical firm's Q2 net loss widened as operating expenses increased for Phase 3 trial
Company reported no revenue for Q2 2026
Cash position expected to fund operations through anticipated Phase 3 topline data readout

Outlook
Company expects to complete Phase 3 CATT1 trial enrollment in Q3 2026
vTv expects to initiate Phase 2a Hybrid CATT1 trial before year end 2026
Company expects cash to fund operations through anticipated CATT1 topline data readout

Result Drivers
PHASE 3 TRIAL COSTS - Co said increased R&D expenses were primarily driven by continued investment in the Phase 3 CATT1 trial
SUPPORT FOR CLINICAL ACTIVITIES - Co said higher G&A expenses reflect ongoing support for corporate operations and clinical development

Company press release: ID:nGNX2krwPX

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Operating Expenses
 
$13.93 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for vTv Therapeutics Inc is $57.00, about 65.7% above its August 5 closing price of $34.39

Reuters Recommended Reads
Aug 6 - Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs
Aug 6 - Ireland's GH Research Q2 net loss widens on higher R&D costs
Aug 4 - Dianthus Therapeutics Q2 net loss widens as R&D costs rise

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)